<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Inst Med Trop Sao Paulo</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev. Inst. Med. Trop. Sao Paulo</journal-id>
      <journal-id journal-id-type="publisher-id">rimtsp</journal-id>
      <journal-title-group>
        <journal-title>Revista do Instituto de Medicina Tropical de S&#xE3;o Paulo</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-4665</issn>
      <issn pub-type="epub">1678-9946</issn>
      <publisher>
        <publisher-name>Instituto de Medicina Tropical</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27049708</article-id>
      <article-id pub-id-type="pmc">4727140</article-id>
      <article-id pub-id-type="doi">10.1590/S0036-46652015000600011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED
VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Carcinoma hepatocelular em paciente n&#xE3;o cirr&#xF3;tico com resposta
virol&#xF3;gica sustentada ap&#xF3;s tratamento para hepatite C</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>de MATTOS</surname>
            <given-names>Angelo Alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MARCON</surname>
            <given-names>Patr&#xED;cia dos Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de ARA&#xDA;JO</surname>
            <given-names>Fernanda Schild Branco</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>CORAL</surname>
            <given-names>Gabriela Perdomo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>TOVO</surname>
            <given-names>Cristiane Valle</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <aff id="aff1">Post-Graduation Course: Hepatology at Universidade Federal de Ci&#xEA;ncias da
Sa&#xFA;de de Porto Alegre (UFCSPA), RS, Brazil</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><bold>Correspondence to:</bold> Patr&#xED;cia dos Santos Marcon, Prof. Annes Dias 295,
Hospital Santa Clara, 7&#xBA; andar, Servi&#xE7;o de Gastroenterologia, Complexo Hospitalar
Santa Casa, Centro Hist&#xF3;rico, 90020-090 Porto Alegre, RS, Brazil. Telephone number:
+55 (51) 95115656. E-mail: <email>patekapel@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Nov-Dec</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2015</year>
      </pub-date>
      <volume>57</volume>
      <issue>6</issue>
      <fpage>519</fpage>
      <lpage>522</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>4</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Chronic infection by hepatitis C virus (HCV) is one of the main risk factors for the
development of liver cirrhosis and hepatocellular carcinoma. However, the emergence
of hepatocellular carcinoma (HCC) in non-cirrhotic HCV patients, especially after
sustained virological response (SVR) is an unusual event. Recently, it has been
suggested that HCV genotype 3 may have a particular oncogenic mechanism, but the
factors involved in these cases as well as the profile of these patients are still
not fully understood. Thus, we present the case of a non-cirrhotic fifty-year-old
male with HCV infection, genotype 3a, who developed HCC two years after treatment
with pegylated-interferon and ribavirin, with SVR, in Brazil.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A infec&#xE7;&#xE3;o cr&#xF4;nica pelo v&#xED;rus da hepatite C &#xE9; um dos principais fatores de risco para
o desenvolvimento de cirrose hep&#xE1;tica e carcinoma hepatocelular. Entretanto, o
surgimento do carcinoma hepatocelular em pacientes portadores de hepatite C na
aus&#xEA;ncia de cirrose, especialmente ap&#xF3;s o tratamento e a obten&#xE7;&#xE3;o de resposta
virol&#xF3;gica sustentada, &#xE9; um evento incomum. Recentemente tem sido sugerido que o
gen&#xF3;tipo 3 do v&#xED;rus da hepatite C possa ter um mecanismo oncog&#xEA;nico particular, mas
todos os fatores envolvidos nestes casos, assim como o perfil destes pacientes, ainda
n&#xE3;o est&#xE3;o totalmente esclarecidos. Deste modo, apresentamos o caso de um paciente
masculino de 50 anos de idade, com infec&#xE7;&#xE3;o pelo v&#xED;rus da hepatite C gen&#xF3;tipo 3a, n&#xE3;o
cirr&#xF3;tico, que desenvolveu carcinoma hepatocelular dois anos ap&#xF3;s ter atingido
resposta virol&#xF3;gica sustentada com o tratamento com interferon peguilado e
ribavirina.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Hepatocellular carcinoma</kwd>
        <kwd>Hepatitis C</kwd>
        <kwd>Genotype 3</kwd>
        <kwd>Sustained virological response</kwd>
        <kwd>Non-cirrhotic liver</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="20"/>
        <page-count count="4"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Chronic infection by hepatitis C virus (HCV) is one of the main risk factors for liver
cirrhosis and hepatocellular carcinoma (HCC) worldwide<xref rid="B06" ref-type="bibr">6</xref>
<sup>,</sup>
<xref rid="B11" ref-type="bibr">11</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">14</xref>. In recent decades, the incidence of HCC seems
to be changing, especially in areas previously considered at low prevalence. This seems
likely to be associated with the increase in the number of cases of HCV-related
cirrhosis in these regions<xref rid="B05" ref-type="bibr">5</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">9</xref>. In Brazil, about 54% of HCC are associated to
HCV-related cirrhosis, according to a national survey<xref rid="B05" ref-type="bibr">5</xref>. In contrast with the hepatitis B virus (HBV) infection, the emergence of
HCC in non-cirrhotic HCV patients is an unusual event<xref rid="B09" ref-type="bibr">9</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">10</xref>. In chronic HCV patients, the risk of HCC is
proportionate to the liver fibrosis stage, with an annual rate of 0.5-10% of developing
HCC in a cirrhotic liver, according to the region studied<xref rid="B11" ref-type="bibr">11</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">14</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">17</xref>. </p>
      <p>The introduction of interferon (IFN) and ribavirin (RBV) in the management of HCV
provided a significant advance in the attempt to modify the natural course of liver
disease in patients with chronic HCV infection<xref rid="B17" ref-type="bibr">17</xref>.
Several studies have examined the effect of this therapy on the incidence of HCC<xref rid="B14" ref-type="bibr">14</xref>
<sup>,</sup>
<xref rid="B15" ref-type="bibr">15</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">17</xref>
<sup>,</sup>
<xref rid="B20" ref-type="bibr">20</xref>. Current data indicate that patients treated
with antiviral therapy, who achieve sustained virological response (SVR) have a
reduction in all-cause mortality, including progression of liver disease<xref rid="B09" ref-type="bibr">9</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">14</xref>. Furthermore, patients with SVR present an
important improvement in hepatic inflammation and fibrosis, and consequently a reduction
in the risk of developing HCC <xref rid="B03" ref-type="bibr">3</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">14</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">17</xref>
<sup>,</sup>
<xref rid="B18" ref-type="bibr">18</xref>. However, the presence of HCC in non-cirrhotic
patients with SVR is possible and Asia practically monopolizes existing accounts,
especially Japan<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>,</sup>
<xref rid="B16" ref-type="bibr">16</xref>. The factors involved in these cases as well
as the profile of these patients are still not fully understood. Thus, we deem it
relevant to describe an unusual case of HCC in a non-cirrhotic patient after HCV
treatment with pegylated IFN (pegIFN) and RBV, years after SVR, in Brazil.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A Caucasian fifty-year-old male had HCV infection diagnosis in routine exams in 2007.
Further evaluation showed a genotype 3a, with a viral load of 156.789 IU/mL by HCV-RNA
quantitative PCR (real time - polymerase chain reaction, reference value &lt; 12 UI/mL)
, baseline gamma-glutamyl transferase (gGT) levels of 90 U/L (normal value: 8-61 U/L)
and elevated aminotransferase levels - serum alanine aminotransferase (ALT) 110 U/L
(normal value: 7-56 U/L) and aspartate aminotransferase (AST) 192 (normal value: 5-40
U/L). The additional laboratory exams showed normal liver function markers (albumin,
bilirubin and prothrombin), negative serum markers for HBV, absence of abnormalities in
blood glucose values and normal hematologic counts. The physical examination revealed a
eutrophic patient and no signs of chronic liver disease. The abdominal ultrasound (US)
was normal and without signs of advanced chronic liver disease or portal hypertension.
There were no reports of comorbidities like diabetes, obesity, other infections, or
alcohol abuse. Liver biopsy was performed and considered representative. A total of two
fragments and 11 portal tracts were analyzed; the length and width of the greatest
fragment was 1.0 x 0.3 cm, respectively. This biopsy showed chronic hepatitis with
intense interface activity and a few fibrous septa (<xref ref-type="fig" rid="f01">Fig.
1</xref>- A and B), classified as Metavir<xref rid="B02" ref-type="bibr">2</xref>
A3-F2. There was no hepatic steatosis or other relevant findings, like siderosis, small
cell change, or even dysplasia. As soon as possible, he began the treatment with pegIFN
and RBV for six months, achieving SVR and normalizing ALT and AST. He remained with
negative HCV-RNA evaluated by real-time PCR, normal aminotransferases, and asymptomatic
for two years, when nonspecific abdominal pain appeared, without other symptoms or alarm
signals. A new abdominal US showed portal vein thrombosis. Thrombophilia was ruled out,
and an abdominal CT scan was performed. Surprisingly, it demonstrated a portal vein
thrombosis with arterial enhancement, associated with nonspecific hypodense nodules in
the right hepatic lobe (<xref ref-type="fig" rid="f02">Fig. 2</xref>). The magnetic
resonance imaging evidenced the same characteristics of portal thrombosis, besides
several nodular images of different sizes, the largest one with 1.8 cm, without typical
vascular pattern<xref rid="B06" ref-type="bibr">6</xref>. The alpha-fetoprotein level
was 4.5U/L. We decided to do a tomography to guide a biopsy of the lesion in the right
lobe and a biopsy away of the lesion, in the left hepatic lobe. The biopsy evidenced a
moderately differentiated HCC with trabecular pattern (<xref ref-type="fig" rid="f01">Fig. 1</xref> - C and D). There was no vessel or stromal invasion documented in the
sample. The non-tumorous liver tissue remained without evidence of cirrhosis - Metavir
A1-F1 (<xref ref-type="fig" rid="f01">Fig. 1</xref> - E and F). Further to this, we
performed immunohistochemistry to confirm the histogenesis of this neoplasia, that
showed positivity for typical antibodies related to hepatocellular carcinoma<xref rid="B10" ref-type="bibr">10</xref> which were hepatocyte-specific antigen (HSA) and
canalicular staining of: pCEA, CD10 and Villin (<xref ref-type="fig" rid="f01">Fig.
1</xref> - G and H). These features, associated with the presence of vascularization
in the portal thrombus, led to the conclusion that the portal thrombosis corresponded to
macrovascular tumor invasion and Sorafenib was prescribed. Despite this, the patient
developed jaundice, signs of portal hypertension, with ascites and variceal bleeding,
progressing to death in four months. </p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>
<bold>-</bold> Histological images. <bold>A</bold> - Pretreatment liver biopsy:
interface activity (hematoxylin-eosin, 100x). <bold>B</bold> - Pretreatment
liver biopsy: fibrous septa (Masson's trichrome, 100x). <bold>C</bold> - Liver
section from the tumor: moderately differentiated HCC (hematoxylin-eosin, 100
x). <bold>D</bold> - Liver section from the tumor: moderately differentiated
HCC in detail (hematoxylin-eosin, 400x). <bold>E</bold> - Post treatment liver
biopsy: non-tumoral tissue with mild activity (hematoxylin-eosin, 40 x).
<bold>F</bold> - Post treatment liver biopsy: portal fibrosis (Masson's
trichrome, 40x). <bold>G</bold> - HCC, immunohistochemistry:
hepatocyte-specific antigen (400 x). <bold>H</bold> - HCC,
immunohistochemistry: CD 10, canalicular staining (400 x).</title></caption><graphic xlink:href="0036-4665-rimtsp-57-06-00519-gf01"/></fig>
</p>
      <p>
<fig id="f02" orientation="portrait" position="float"><label>Fig. 2</label><caption><title>
<bold>-</bold> Abdominal computadorized tomography scan in different sections:
note the portal vein thrombosis and nonspecific hypodense nodules in the right
hepatic lobe.</title></caption><graphic xlink:href="0036-4665-rimtsp-57-06-00519-gf02"/></fig>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The incidence of HCC in patients without advanced hepatic fibrosis, years after
treatment for HCV and with SVR, has been reported in Asian patients, particularly in
Japanese ones<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>,</sup>
<xref rid="B18" ref-type="bibr">18</xref>, where HCV infection is endemic and the
prevalence of HCC is high. In the Occident, we found few similar cases published in the
literature<xref rid="B03" ref-type="bibr">3</xref>
<sup>,</sup>
<xref rid="B19" ref-type="bibr">19</xref>, one of the reasons why we deem important to
present this case. </p>
      <p>In the United States, when LOK <italic>et al</italic>.<xref rid="B11" ref-type="bibr">11</xref> assessed the role of maintaining reduced doses of pegIFN in patients with
chronic HCV liver disease, in order to prevent complications, they demonstrated the
existence of HCC in patients without cirrhosis, but emphasizing the importance of the
presence of advanced fibrosis. The case presented here is relevant since it shows an HCC
that affects a patient with HCV and without advanced fibrosis, two years after SVR, and
with documented fibrosis regression outside the tumor area. Previous studies have
strongly suggested that SVR can minimize the histological and clinical deterioration,
resulting in improvement of liver histology<xref rid="B07" ref-type="bibr">7</xref>. The
benefits of successful antiviral therapy in chronic HCV has been recently reaffirmed by
MOON <italic>et al</italic>.<xref rid="B13" ref-type="bibr">13</xref> in a study that
retrospectively reviewed 463 patients who underwent pegIFN and RBV therapy, where
patients without cirrhosis and with SVR had a significant lower risk of progression to
cirrhosis compared to non-SVR and, moreover, SVR was related to reduction in the risk of
HCC development. As in the present case, MOON <italic>et al</italic>.<xref rid="B13" ref-type="bibr">13</xref> also found two patients with SVR and no evidence
of cirrhosis before HCC diagnosis. However, the exclusion of cirrhosis in these two
patients was made based on clinical criteria, which is not a reliable method to assess
if advanced fibrosis has already been detected histologically. In the presented case,
two biopsies at different times, including the diagnosis of HCC, have pointed to the
absence of significant fibrosis.</p>
      <p>It is suggested that the risk factors for the development of HCC in the absence of
advanced fibrosis in HCV pretreatment patients are male gender, advanced age,
persistently elevated aminotransferases, hepatic steatosis, diabetes, and alcohol
abuse<xref rid="B03" ref-type="bibr">3</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">9</xref>. The frequent association of HCV, especially
genotype 3, with steatosis deserves mention in this context, as this parameter
correlates with HCC<xref rid="B08" ref-type="bibr">8</xref>. In this case, despite being
male and genotype 3, the patient had none of the other afore mentioned risk factors,
including absence of steatosis on pretreatment and tumor biopsies.</p>
      <p>In HCV eradicated patients, risk factors for the development of HCC remain not entirely
clear. SATO <italic>et al</italic>.<xref rid="B17" ref-type="bibr">17</xref> reported
that in their experience, men with documented advanced liver fibrosis, and low levels of
serum albumin and elevated pretreatment alpha-fetoprotein, are more likely to develop
HCC within five years of HCV eradication. All these findings suggest a possible more
advanced liver disease as the basis for development of HCC; however, these features
curiously did not occur in the present case.</p>
      <p>Recently, other risk factors for the development of HCC, independent of the degree of
hepatic fibrosis, have been studied. HUANG <italic>et al</italic>.<xref rid="B09" ref-type="bibr">9</xref>, in a prospective cohort of 642 individuals, found an interesting
association between high baseline gGT levels before IFN-based anti-HCV therapy using a
cut-off value of 75U/L and development of HCC in non-cirrhotic patients with SVR, but
the pathophysiological mechanism of this association remains unclear. Furthermore, the
possibility that the genotype 3 HCV might have a particular oncogenic process has been
considered, possibly by means of alteration in chromosome 10, causing disturbances in
tumor suppression and increasing the incidence of HCC, which could remain even after HCV
clearance and independent of the fibrosis degree<xref rid="B08" ref-type="bibr">8</xref>. In the present case, the hypothesis that genotype 3 may have an important
role in the emergence of HCC should be considered, as well as high baseline gGT levels,
especially in this context of lack of significant fibrosis.</p>
      <p>In current literature, recommendations for monitoring and surveillance of these patients
with chronic HCV without cirrhosis are scanty and conflicting. The American Association
for the Study of Liver Diseases<xref rid="B04" ref-type="bibr">4</xref> describes that
the benefit of maintaining surveillance in patients with HCV and Metavir F3 is
uncertain, not routinely recommended. On the other hand, the European Association for
the Study of the Liver<xref rid="B06" ref-type="bibr">6</xref> recommended that patients
with chronic HCV and Metavir F3 should be included in surveillance programs, since the
transition to cirrhosis cannot be accurately defined. These same authors also recommend
maintaining surveillance in patients treated for HCV who have advanced fibrosis, even
after SVR.</p>
      <p>In conclusion, the possibility of developing HCC in patients without advanced fibrosis
suggests the existence of other factors that are still unclear in the pathogenesis of
HCV, raising questions regarding the need to perform the follow-up of these patients,
even after SVR. The new evidence that HCV genotype 3 has become a problem in hepatitis C
patients either by the response rate to IFN-free therapy regimens or the possibility of
independent mechanisms of carcinogenesis<xref rid="B08" ref-type="bibr">8</xref>, a
point that needs further studies. </p>
    </sec>
    <sec>
      <title>ABBREVIATIONS</title>
      <p>HCV - Hepatitis C virus</p>
      <p>HCC - Hepatocellular carcinoma</p>
      <p>HBV - Hepatitis B virus</p>
      <p>IFN - Interferon</p>
      <p>RBV - Ribavirin</p>
      <p>SVR - Sustained virologic response</p>
      <p>pegIFN - Pegylated interferon</p>
      <p>PCR - Polymerase chain reaction</p>
      <p>gGT - Gamma-glutamyl transferase</p>
      <p>ALT - Alanine aminotransferase </p>
      <p>AST - Aspartate aminotransferase</p>
      <p>US - Ultrasound</p>
      <p>HSA - Hepatocyte-specific antigen </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al Nozha</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Al Ashgar</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Al Mana</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular carcinoma in the absence of liver cirrhosis in a
treated hepatitis C virus patient</article-title>
          <source>Ann Saudi Med</source>
          <year>2009</year>
          <volume>29</volume>
          <fpage>235</fpage>
          <lpage>236</lpage>
          <pub-id pub-id-type="pmid">19448362</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bedossa</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Poynard</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>An algorithm for the grading of activity in chronic hepatitis
C</article-title>
          <source>The METAVIR Cooperative Study Group. Hepatology</source>
          <year>1996</year>
          <volume>24</volume>
          <fpage>289</fpage>
          <lpage>293</lpage>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bertolini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bassi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fornaciari</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Development of hepatocellular carcinoma in a non-cirrhotic, long-term
responder to antiviral therapy, chronic hepatitis C patients: what kind of
surveillance?</article-title>
          <source>Ann Gastroenterol</source>
          <year>2013</year>
          <volume>26</volume>
          <fpage>80</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">24714548</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bruix</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>M</given-names>
            </name>
            <collab>American Association for the Study of Liver Diseases</collab>
          </person-group>
          <article-title>Management of hepatocellular carcinoma: an update</article-title>
          <source>Hepatology</source>
          <year>2011</year>
          <volume>53</volume>
          <fpage>1020</fpage>
          <lpage>1022</lpage>
          <pub-id pub-id-type="pmid">21374666</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carrilho</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Kikuchi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Branco</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alves</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Mattos</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Brazilian HCC Study</surname>
              <given-names>Group</given-names>
            </name>
          </person-group>
          <article-title>Clinical and epidemiological aspects of hepatocellular carcinoma in
Brazil</article-title>
          <source>Clinics</source>
          <year>2010</year>
          <volume>65</volume>
          <fpage>1285</fpage>
          <lpage>1290</lpage>
          <pub-id pub-id-type="pmid">21340216</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>European Association for the Study of the Liver, European Organization for
Research and Treatment of Cancer</collab>
          </person-group>
          <article-title>EASL-EORTC clinical practice guidelines: management of hepatocellular
carcinoma</article-title>
          <source>J Hepatol</source>
          <year>2012</year>
          <volume>56</volume>
          <fpage>908</fpage>
          <lpage>943</lpage>
          <pub-id pub-id-type="pmid">22424438</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Bacon</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Brunt</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Mihindukulasuriya</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Di Bisceglie</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Clinical, virologic, histologic, and biochemical outcomes after
successful HCV therapy: a 5-year follow-up of 150 patients</article-title>
          <source>Hepatology</source>
          <year>2009</year>
          <volume>49</volume>
          <fpage>729</fpage>
          <lpage>738</lpage>
          <pub-id pub-id-type="pmid">19072828</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goossens</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Negro</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Is genotype 3 of the hepatitis C virus the new
villain?</article-title>
          <source>Hepatology</source>
          <year>2014</year>
          <volume>59</volume>
          <fpage>2403</fpage>
          <lpage>2412</lpage>
          <pub-id pub-id-type="pmid">24155107</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Yeh</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Hsieh</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Hsieh</surname>
              <given-names>MY</given-names>
            </name>
          </person-group>
          <article-title>Baseline gamma-glutamyl transferase levels strongly correlate with
hepatocellular carcinoma development in non-cirrhotic patients with successful
hepatitis C virus eradication</article-title>
          <source>J Hepatol</source>
          <year>2014</year>
          <volume>61</volume>
          <fpage>67</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">24613362</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karabork</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kaygusuk</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ekinci</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>The best immunohistochemical panel for differentiating hepatocellular
carcinoma from metastatic adenocarcinoma</article-title>
          <source>Pathol Res Pract</source>
          <year>2010</year>
          <volume>206</volume>
          <fpage>572</fpage>
          <lpage>577</lpage>
          <pub-id pub-id-type="pmid">20400233</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lok</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Seeff</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Di Bisceglie</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Sterling</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Curto</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Incidence of hepatocellular carcinoma and associated risk factors in
hepatitis C-related advanced liver disease</article-title>
          <source>Gastroenterology</source>
          <year>2009</year>
          <volume>136</volume>
          <fpage>138</fpage>
          <lpage>148</lpage>
          <pub-id pub-id-type="pmid">18848939</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyano</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Togashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shinzawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sugahara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsuo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Case report: occurrence of hepatocellular carcinoma 4</article-title>
          <source>5 years after successful treatment with virus clearance for chronic hepatitis
C. J Gastroenterol Hepatol</source>
          <year>1999</year>
          <volume>14</volume>
          <fpage>928</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="pmid">10535477</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Kim do</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Baatarkhuu</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
          <article-title>Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis
C patients with sustained virological response by pegylated interferon and
ribavirin</article-title>
          <source>Dig Dis Sci</source>
          <year>2015</year>
          <volume>60</volume>
          <fpage>573</fpage>
          <lpage>581</lpage>
          <pub-id pub-id-type="pmid">25236421</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morgan</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Baack</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Yartel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pitasi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Falck-Ytter</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Eradication of hepatitis C virus infection and the development of
hepatocellular carcinoma: a meta-analysis of observational studies</article-title>
          <source>Ann Intern Med</source>
          <year>2013</year>
          <volume>158</volume>
          <fpage>329</fpage>
          <lpage>337</lpage>
          <pub-id pub-id-type="pmid">23460056</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ng</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Saab</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Effects of a sustained virologic response on outcomes of patients with
chronic hepatitis C</article-title>
          <source>Clin Gastroenterol Hepatol</source>
          <year>2011</year>
          <volume>9</volume>
          <fpage>923</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="pmid">21699815</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nojiri</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugimoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shiraki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kusagawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Beppu</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Development of hepatocellular carcinoma in patients with chronic
hepatitis C more than 10 years after sustained virological response to interferon
therapy</article-title>
          <source>Oncol Lett</source>
          <year>2010</year>
          <volume>1</volume>
          <fpage>427</fpage>
          <lpage>430</lpage>
          <pub-id pub-id-type="pmid">22966320</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sato</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kumada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Izumi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Asahina</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Clinical characteristics of patients who developed hepatocellular
carcinoma after hepatitis C virus eradication with interferon therapy: current
status in Japan</article-title>
          <source>Intern Med</source>
          <year>2013</year>
          <volume>52</volume>
          <fpage>2701</fpage>
          <lpage>2706</lpage>
          <pub-id pub-id-type="pmid">24334571</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sewell</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Stick</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Monto</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular carcinoma after sustained virologic response in
hepatitis C patients without cirrhosis on a pretreatment liver
biopsy</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2009</year>
          <volume>21</volume>
          <fpage>225</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="pmid">19212213</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tabibian</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Landaverde</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Winn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Geller</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Nissen</surname>
              <given-names>NN</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular carcinoma in a hepatitis C patent with sustained viral
response and no fibrosis</article-title>
          <source>Ann Hepatol</source>
          <year>2009</year>
          <volume>8</volume>
          <fpage>64</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">19221537</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Jia</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Ge</surname>
              <given-names>YS</given-names>
            </name>
          </person-group>
          <article-title>Effects of interferon treatment on development and progression of
hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis
of randomized controlled trials</article-title>
          <source>Int J Cancer</source>
          <year>2011</year>
          <volume>129</volume>
          <fpage>1254</fpage>
          <lpage>1264</lpage>
          <pub-id pub-id-type="pmid">21710498</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
